Inovio Pharma (INO) |
|
16.94 1.57 (10.21%)
|
09-27 22:06 |
|
Open: |
15.85 |
Pre. Close: |
15.37 |
|
High:
|
16.96 |
Low:
|
15.86 |
|
Volume:
|
13,539,826 |
Market Cap:
|
2,838M |
|
|
|
|
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. The company is headquartered in San Diego, California and currently employs 281 full-time employees. The firm's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. The company has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
16.968 - 17.07 |
17.07 - 17.169 |
|
Low:
|
15.629 - 15.744 |
15.744 - 15.854 |
|
Close:
|
16.754 - 16.933 |
16.933 - 17.104 |
|
Technical analysis |
as of: 2020-09-25 4:31:28 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 21.83 One year: 25.50 |
| Support: |
Support1: 12.57 Support2: 8.78 |
| Resistance: |
Resistance1: 18.69 Resistance2: 21.83 |
| Pivot: |
13.89 |
| Moving Average: |
MA(5): 16.59  MA(20): 13.21
MA(100): 16.83 MA(250): 9.60 |
| MACD: |
MACD(12,26): 0.50 Signal(9): -0.21 |
| Stochastic oscillator: |
%K(14,3): 73.80 %D(3): 76.63 |
| RSI: |
RSI(14): 57.13 |
| 52-week: |
High: 33.79 Low: 1.92 Change(%): 726.3 |
| Average Vol(K): |
3-Month: 2419798 10-Days: 3980967 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.INO has closed below upper band by 26.8%. Bollinger Bands are 33.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 27 Sep 2020
If You Invested $1,000 in Inovio Pharmaceuticals in January, This Is How Much You'd Have Now - Motley Fool
Sat, 26 Sep 2020
Is Inovio Worth Buying During the Market Correction? - The Motley Fool
Fri, 25 Sep 2020
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Has Recovered 87.51% So Far, But Another 119.84% Gain Cannot Be Ruled Out - Marketing Sentinel
Wed, 23 Sep 2020
Why Inovio Pharmaceuticals Stock Is Down Today - Motley Fool
Tue, 22 Sep 2020
3 Critical Catalysts on the Way for Inovio - Motley Fool
Mon, 21 Sep 2020
Inovio Pharmaceuticals Stock Could See More Downside From $16 - Forbes
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
168 |
| Shares Float (M) |
164 |
|
% Held by Insiders
|
2.69 |
|
% Held by Institutions
|
29.41 |
|
Shares Short (K)
|
51,820 |
|
Shares Short P. Month (K)
|
38,400 |
Stock Financials |
|
EPS
|
-1.850 |
|
EPS Est This Year
|
-0.950 |
|
EPS Est Next Year
|
-1.200 |
|
Book Value (p.s.)
|
1.170 |
|
Profit Margin
|
|
|
Operating Margin
|
-4045.74 |
|
Return on Assets (ttm)
|
-22.8 |
|
Return on Equity (ttm)
|
-184.5 |
|
Qtrly Rev. Growth
|
96.9 |
|
Gross Profit (p.s.)
|
-0.490 |
|
Sales Per Share
|
0.016 |
|
EBITDA (p.s.)
|
-0.637 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-94 |
|
Levered Free Cash Flow (M)
|
-52 |
Stock Valuations |
|
PE Ratio
|
-9.16 |
|
PEG Ratio
|
|
|
Price to Book value
|
14.48 |
|
Price to Sales
|
1035.69 |
|
Price to Cash Flow
|
-30.16 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
